-
Neuphoria Therapeutics adopts stockholder rights plan amid stock accumulation
-
Lucid Capital Markets Downgrades Neuphoria Therapeutics Inc. (NEUP) to Neutral
-
Neuphoria completes phase 3 trial milestone for anxiety drug BNC-210
-
Neuphoria Therapeutics Inc. (NEUP) PT Raised to $35 at Maxim Group
-
Neuphoria (NEUP) to Receive $15M Milestone Payment from Merck
-
Neuphoria (NEUP) Files $100M Mixed Shelf

